旁听FDA policy的课对找工作帮助大吗# Biology - 生物学
n*s
1 楼
拿不到学分，只是旁听，最后可以给一个certificate。泛泛而谈的话，我估计肯定是
有帮助的，问题是我现在很困难的权衡着。一边是由于个人原因终于有点时间想全心做
实验，发篇文章对自己博后生涯有个交代。另外一边，万一努力了还是到最后没有
publication，那就更难找工作，到时候如果想进industry，scientists估计没戏了，
如果上了这个课，指不准还能对找其它类工作有点帮助。问题是想把这个课
certificate拿到貌似还是要很多时间的，我肯定不能全心扑在实验上。所以想问一下
，尤其是industry的，我这种情况旁听这课的benefits是不是overweighing。唉，年纪
大了，家有小娃要养，没有时间造啊，每一个决定都小心翼翼～这课每周一次，两小时
，持续整个spring semester，schedule大概是这个样子：
Session 1 (Jan 22): Introduction to FDA and Forum for Collaborative HIV
Research
Session 2 (Jan 29): Standards for Efficacy
Session 3 (Feb 5): Ethics and Informed Consent; Case studies from HIV
Session 4 (Feb 12): Pharmacology & Pharmacodynamics (PK/PD); Good Laboratory
Practice (GLP)
Session 5 (Feb 19): Surrogate Endpoints & Accelerated Approval Pathways;
FDASIA 2012; Case studies from HIV, HCV and CMV
Session 6 (Feb 26): Pathways for Biomarker Acceptance; Case studies from
liver fibrosis and NASH
Session 7 (Mar 5): Special Challenges in HIV Cure Research
Session 8 (Mar 12): Toxicology
Session 9 (Mar 19): New Indications, New Formulations (pediatric, generic,
PrEP, microbicides)
Session 10 (Apr 2): Safety and Pharmacovigilance; Risk Evaluation and
Mitigation Strategies (REMS)
Session 11 (Apr 9): Response to Global Epidemics *Open, public, lecture*
Session 12 (Apr16): Chemistry, Manufacturing & Control (CMC)
Sessions 13 and 14 (April 23 and 30): Student presentations of drug
development case studies
跪谢各种建议！
有帮助的，问题是我现在很困难的权衡着。一边是由于个人原因终于有点时间想全心做
实验，发篇文章对自己博后生涯有个交代。另外一边，万一努力了还是到最后没有
publication，那就更难找工作，到时候如果想进industry，scientists估计没戏了，
如果上了这个课，指不准还能对找其它类工作有点帮助。问题是想把这个课
certificate拿到貌似还是要很多时间的，我肯定不能全心扑在实验上。所以想问一下
，尤其是industry的，我这种情况旁听这课的benefits是不是overweighing。唉，年纪
大了，家有小娃要养，没有时间造啊，每一个决定都小心翼翼～这课每周一次，两小时
，持续整个spring semester，schedule大概是这个样子：
Session 1 (Jan 22): Introduction to FDA and Forum for Collaborative HIV
Research
Session 2 (Jan 29): Standards for Efficacy
Session 3 (Feb 5): Ethics and Informed Consent; Case studies from HIV
Session 4 (Feb 12): Pharmacology & Pharmacodynamics (PK/PD); Good Laboratory
Practice (GLP)
Session 5 (Feb 19): Surrogate Endpoints & Accelerated Approval Pathways;
FDASIA 2012; Case studies from HIV, HCV and CMV
Session 6 (Feb 26): Pathways for Biomarker Acceptance; Case studies from
liver fibrosis and NASH
Session 7 (Mar 5): Special Challenges in HIV Cure Research
Session 8 (Mar 12): Toxicology
Session 9 (Mar 19): New Indications, New Formulations (pediatric, generic,
PrEP, microbicides)
Session 10 (Apr 2): Safety and Pharmacovigilance; Risk Evaluation and
Mitigation Strategies (REMS)
Session 11 (Apr 9): Response to Global Epidemics *Open, public, lecture*
Session 12 (Apr16): Chemistry, Manufacturing & Control (CMC)
Sessions 13 and 14 (April 23 and 30): Student presentations of drug
development case studies
跪谢各种建议！